Argus Research analyst Kevin Heal downgrades AGNC Investment (NASDAQ:AGNC) from Buy to Hold.
Adamis Pharmaceuticals Q3 EPS $(0.03), Inline, Sales $1.51M Beat $500.00K Estimate
Adamis Pharmaceuticals (NASDAQ:ADMP) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.06) per share from the same period last year.